Search Results

In a deal expected to close in Q1 2025, Roche will gain access to Poseida’s off-the-shelf CAR T candidates.

Poseida Therapeutics, Inc. announced that its virtual Annual Meeting of Stockholders will be held on Monday, June 17, 2024 at 1:00 p.m. PT.

Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer and rare diseases, today announced updates and financial results for the first quarter ended March 31, 2024.

Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the appointment of Syed Rizvi, M.D., as Chief Medical Officer effective April 1, 2024.

Poseida Therapeutics, Inc. announced that the Compensation Committee of its Board of Directors granted an inducement award to Syed Rizvi, M.D., the Company’s new Chief Medical Officer.

Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Poseida Therapeutics, Inc. (NASDAQ: PSTX, CEO: Mark Gergen, “Poseida”) today announced a strategic investment to support the advancement of Poseida’s commitment to redefining cancer cell therapy.

Poseida Therapeutics, Inc. today announced that the Company will participate in the following upcoming investor conferences in November.